GlassScriptPhysician profile
Xiaolin Zhang
NPI 1588311633
$3,127.15
in general payments reported to CMS, 2019-2025
25 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $323 · 2023: $888 · 2024: $850 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $673.35 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $319.05 | 2022-2025 | |
| Amgen INC. | $245.23 | 2023-2025 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $238.34 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $226.27 | 2022-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $210.66 | 2023-2025 | |
| Abbvie INC. | $194.90 | 2022-2025 | |
| Lilly USA, LLC | $169.87 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.23 | 2022-2025 | Jardiance |
| Dexcom, INC. | $129.20 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $127.36 | 2022-2025 | |
| Glaxosmithkline, LLC. | $106.01 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.75 | 2024-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $58.10 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $31.78 | 2022-2023 | Belsomra, Steglatro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $26.42 | 2025 | |
| Tanabe Pharma America, INC. | $23.75 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.61 | 2022 | |
| Amarin Pharma, INC. | $19.41 | 2022 | |
| Echosens North America, INC. | $19.04 | 2024 | Fibroscan |
| Sanofi-Aventis U.S. LLC | $17.81 | 2022 | |
| Shield Therapeutics INC | $16.21 | 2022 | |
| Redhill Biopharma INC. | $15.09 | 2022 | |
| Hikma Pharmaceuticals USA | $14.38 | 2025 | Ryaltris |
| Janssen Pharmaceuticals, INC | $13.33 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaolin Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.